Novo Nordisk's investigational drug zenagamtide has shown promising results in reducing A1C levels and body weight in adults with type 2 diabetes. In a phase 2 trial, up to 89.1% of participants achieved A1C below 7%, with a weight loss of up to 14.6% after 36 weeks, leading to plans for phase 3 trials.

• 01The phase 2 trial involved 262 adults with type 2 diabetes inadequately controlled on metformin.
• 02Zenagamtide achieved an A1C reduction of up to -1.71% at the highest dose of 40 mg compared to placebo.
• 03Participants experienced body weight loss of up to 14.6%, with the baseline average weight around 219 lbs.
• 0489.1% of participants on zenagamtide reached A1C levels below 7%, and 76.2% achieved levels at or below 6.5%.
• 05Novo Nordisk plans to initiate phase 3 clinical trials for zenagamtide in the second half of 2026.

The results from the zenagamtide trial could significantly enhance treatment options for the approximately 40.1 million people in the U.S. with diabetes, particularly those with type 2 diabetes.